前列腺特异性抗原密度预测模型对跨年龄层临床显著前列腺癌的一致预测能力
Kamil Malshy1, Anna Ochsner1, Alexander Homer2
1The Minimally Invasive Urology Institute, The Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
The Prostate
|June 20, 2024
概括
前列腺特异性抗原密度 (PSAD) 有效地预测了跨年龄组的临床显著前列腺癌 (csPCa). 虽然PSAD在年轻男性中显示出高负预测值,但由于疾病患病率较高,其积极预测值随着年龄的增长而增加.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
背景情况:
- 预检前列腺特异性抗原密度 (PSAD) 是临床显著前列腺癌 (csPCa) 的关键预测因素.
- 前列腺特异性抗原 (PSA) 和前列腺体积 (PV) 自然会随着年龄的增长而增加,这可能会影响 PSAD 值.
- 对于csPCa,PSAD的预测准确性在不同年龄层可能有所不同.
研究的目的:
- 评估在不同年龄组中对csPCa的PSAD的预测性能.
- 确定是否需要特定年龄的PSAD值来准确预测csPCa.
主要方法:
- 对1913名接受多参数核磁共振和前列腺活检的患者 (2016-2021) 的回顾性分析.
- 患者被分为四个年龄组:<55,55-64,65-74岁和≥75岁.
- 曲线下的面积 (AUC) 评估了PSAD对csPCa (格里森等级组≥2) 的预测准确性;对于0.1,0.15和0.2.2的PSAD值,分析了灵敏度,特异性,正预测值 (PPV) 和负预测值 (NPV).
主要成果:
- 在四个年龄组中没有观察到PSAD中位数的显著差异 (p=0.393).
- csPCa的患病率随着年龄的增长而增加,从最年轻组的16.1%增加到最年长组的46.7%.
- 对于csPCa的PSAD AUC预测在各年龄组的0.68到0.75之间;PSAD值为0.15显示了随着年龄的增长增加PPV和减少NPV的趋势.
结论:
- 对csPCa的PSAD预测模型在不同年龄组中表现相似.
- 年轻患者对PSAD呈现高NPV,但低PPV,而老年患者则呈现相反的趋势,与较高的疾病患病率有关.
- 在老年人中,PSAD值在排除csPCa方面可能不那么有效,因此需要个性化临床评估.
相关概念视频
Sensitivity, Specificity, and Predicted Value
277
In healthcare diagnostics, laboratory tests play a crucial role in identifying and diagnosing a wide range of medical conditions. However, interpreting test results is not always straightforward. An abnormal test result does not always confirm the presence of a disease, just as a normal result does not guarantee its absence. To assess the reliability of these diagnostic tools, healthcare practitioners rely on two key statistical indicators: sensitivity and specificity.
Sensitivity is the...
Sensitivity is the...
277
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342


